Athens Research/Cambio - Excellence in Molecular Biology/10 pouches/MC-12-9222-10

价格
面议
货号:MC-12-9222-10
浏览量:61
品牌:Athens Research
服务
全国联保
正品保证
正规发票
签订合同
商品描述
Lab Reagents

Lab Reagents: Smart Buffers and Reagents

Biological buffers for the life science laboratory need to meet a wide array of criteria. These include good stability, lack of toxicity, precision in pH, pKa between 6.0 and 8.0 (the region in which most biological reactions occur), minimal salt effects due to the ionic composition of the solution, free of enzymatic and hydrolytic activity and minimal participation in biological reactions. Buffers for molecular biology applications, e.g. Tris-Borate-EDTA and Tris-Acetate-EDTA, need to be free from DNAse and RNAse activity. Medicago"s SmartBuffers meet all these criteria. They are manufactured using highly purified, analytical grade chemicals and are extensively quality tested. Manufacturing is done in a controlled clean environment according to GMP procedures. A high level of automation essentially avoids operator intervention and contact with the products. SmartBuffers are supplied as exactly pre-weighed tablets packed in containers or blister packs or as exactly pre-weighed powder mixes packed in sealed aluminium foil pouches. •Pre-mixed powder buffers or tablets with pre-set pH•Analytical grade reagents •Eliminates calculation, formulation and weighing errors •Dissolve-and-go for greater convenience •Stable at room temperature for at least 3 years •Guaranteed reproducibility

  • Catalogue
  • Description
  • Applications & Benefits

Tris-Glycine SDS buffer pH 8.3

Tris-glycine-SDS buffer (TG-SDS) contains the denaturing agent sodium dodecyl sulphate (SDS). Protein electrophoresis under denaturing conditions (SDS-PAGE) involves separating proteins based on their size. By treating the sample under denaturing and reducing conditions with SDS, proteins unfold and become coated with SDS detergent molecules.

Medicago AB

Catalogue No.DescriptionPack SizePriceQty
  • Change to:
  • €
MC-12-9222-10Tris-Glycine SDS buffer pH 8.3, 1000 ml10 pouches£45.00QuantityAdd to Order
MC12-9223-10Tris-Glycine SDS buffer pH 8.3, 5000 ml10 pouches£99.00QuantityAdd to Order

Tris-Glycine SDS buffer pH 8.3

Tris-glycine-SDS buffer (TG-SDS) contains the denaturing agent sodium dodecyl sulphate (SDS). Protein electrophoresis under denaturing conditions (SDS-PAGE) involves separating proteins based on their size. By treating the sample under denaturing and reducing conditions with SDS, proteins unfold and become coated with SDS detergent molecules.

Medicago AB

Product description

Features

  • Running buffers for protein electrophoresis
  • Formulated from analytical grade reagents
  • Assured consistency from lot to lot
  • Exactly pre-weighed powder mix in pouches
  • Dissolve and use in minutes

Product description

Tris-glycine-SDS buffer (TG-SDS) contains the denaturing agent sodium dodecyl sulphate (SDS). Protein electrophoresis under denaturing conditions (SDS-PAGE) involves separating proteins based on their size. By treating the sample under denaturing and reducing conditions with SDS, proteins unfold and become coated with SDS detergent molecules.

Medicago’s TG-SDS buffer is supplied as pre-weighed powder mixes in sealed pouches giving 1000 ml or 5000 ml of 0.025 M Tris, 0.192 M glycine, 0.10% SDS with pH 8.3 at 25°C.

Applications

  • Protein electrophoresis
  • Denatured protein electrophoresis
  • Polyacrylamide gel electrophoresis
  • Western blotting

Directions for use

Empty one pouch of TG-SDS buffer in a laboratory flask or beaker placed on a magnetic stirrer. Add deionized water and stir the solution for a few minutes.Adjust the volume up to 1000 ml or 5000 ml, stir until full dissolution and the buffer solution is ready to use.

Shipping and storage

The TG-SDS buffers are shipped at room temperature. Store the pouches in a dry place at room temperature. Shelf life is three years after production date.

Specifications

Chemicals: Analytical grade

Format: Exactly pre-weighed powder mix

Concentration: 0.025 M Tris,0.192 M glycine,0.10% SDS

Volume: 1000 ml and 5000 ml

pH: 8.3 ± 0.2 at 25°C

MSDS:
application/pdf iconMSDS

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Tris-Glycine SDS buffer pH 8.3

Tris-glycine-SDS buffer (TG-SDS) contains the denaturing agent sodium dodecyl sulphate (SDS). Protein electrophoresis under denaturing conditions (SDS-PAGE) involves separating proteins based on their size. By treating the sample under denaturing and reducing conditions with SDS, proteins unfold and become coated with SDS detergent molecules.

Medicago AB

Applications

  • Protein electrophoresis
  • Denatured protein electrophoresis
  • Polyacrylamide gel electrophoresis
  • Western blotting

If you cannot find the answer to your problem below then please contact us or telephone 01954 210 200

Myeloperoxidase Enzyme Immunoassay Kit 髓过氧化物酶 免疫分析试剂盒 Human MPO EIA KIT FEATURES: USE - Measure human MPO in a variety of matrices SAMPLE -Serum, Platelet-Poor Heparin Plasma, Saliva, Urine or Tissue Culture Media SAMPLES / KIT - 40 in duplicate SENSITIVITY - 0.068 ng/mL STABILITY - liquid reagents stable at 4°C QUICK RESULTS - 2.5 HOURS Myeloperoxidase (MPO) is a tetrameric heme-containing protein abundantly produced in neutrophil granulocytes where it plays an important anti-microbial role. During degranulation MPO is released into the extracellular space. There, as part of the neutrophils “respiratory burst”, it produces hypochlorous acid from hydrogen peroxide and Cl–. MPO also uses hydrogen peroxide to oxidize tyrosine to the tyrosyl radical. Both hypochlorous acid and tyrosyl are cytotoxic and when present can kill bacteria and other pathogens. Hereditary deficiency of myeloperoxidase predisposes individuals to immune deficiency. Studies have shown an association between elevated MPO levels and coronary artery disease, and in 2003 it was suggested that MPO may serve as a sensitive predictor of myocardial infarction in patients complaining of chest pain. Since that time the clinical utility of MPO testing in cardiac patients has been solidly established in the literature with well over 100 papers published. In 2010 this clinical application was further refined by additional studies which determined that measuring both MPO and C-reactive protein (CRP) provided more accurate prediction of mortality risk than measuring just CRP alone.